Background: The aim of the study was to investigate the clinical results of laser atherectomy in the treatment of peripheral arterial disease.
Methods: Retrospective analysis of consecutive patients underwent laser atherectomy at a single institution during a 7-year period by vascular surgeons and interventional cardiologists in a tertiary university-affiliated hospital. Clinical data were retrieved from patient charts and hospital electronic medical records along with the associated arteriograms.
Results: A total of 461 lesions in 343 limbs were treated in 300 patients with a mean age of 70 years. The indication was critical limb ischemia (CLI) with rest pain or tissue loss in 227 (66%) of interventions and claudication in 116 (34%). All procedures included an associated balloon angioplasty, while stenting was performed in 33%. Technical success was achieved in 99% with only 2 (<1%) cases with an acute procedure-related complication requiring surgical intervention. At a mean follow-up of 28 months (range, 1-87 months; median 24 months), 156 patients (45%) became asymptomatic or achieved significant clinical improvement (resolution of tissue loss or rest pain), 60 (17%) remained with CLI, 30 (9%) had a major proximal amputation, and 18 (5%) had a minor amputation. Freedom from major amputation was 90% at 5 years by life-table analysis. Univariate statistical analysis demonstrated the risk of a major amputation to be associated with diabetes, hemodialysis, and tissue loss (P < 0.05 to P < 0.005), while multivariate logistic regression analysis indicated diabetes to be overwhelmingly important (RR: 4.84; 95% confidence interval [CI]: 1.1-21.3; P < 0.05). In a similar manner, multivariate analysis indicated dialysis (RR: 2.46; 95% CI: 1.01-5.98; P < 0.05) and CLI (RR: 2.27; 95% CI: 1.42-3.65; P < 0.01) were associated with higher likelihood for lack of clinical improvement. There was no difference in major amputation rates between surgeons and interventional cardiologists (RR: 1.5; 95% CI: 0.7-2.1; P < 0.1) although it was 3 times more likely for the patients treated by surgeons to suffer from CLI (odds ratio: 3.2; 95% CI: 1.9-5.4; P < 0.0001).
Conclusions: Laser atherectomy is a safe and useful adjunct in limb salvage. Diabetics have much higher probability of requiring a proximal amputation, while those on dialysis and with CLI are least likely to gain clinical benefit.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.avsg.2017.04.013 | DOI Listing |
J Vasc Interv Radiol
December 2024
Department of Interventional Radiology, Mallinckrodt Institute of Radiology, 510 S Kingshighway Blvd, St. Louis, MO 63110.
Purpose: To evaluate the primary use of a laser atherectomy-thrombectomy system in patients with acute limb ischemia (ALI).
Materials And Methods: A single-center retrospective review of patients presenting with ALI (14 days or less) from August 2021 to February 2024 treated primarily with a laser atherectomy-thrombectomy system (Auryon; Angiodynamics, Queensbury, New York) was performed. Technical success was defined by resolution of the acute occlusion with adequate inflow and outflow with pedal signals detectable by handheld doppler ultrasound.
Prog Cardiovasc Dis
December 2024
The Christ Hospital Heart & Vascular Institute and The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio, USA.. Electronic address:
The presence and severity of calcified coronary plaque negatively impacts angiographic and clinical outcomes following percutaneous coronary intervention (PCI). Severe coronary calcification is associated with suboptimal stent delivery, deployment, apposition and expansion which can lead to in-stent restenosis and/or thrombosis. Severe coronary calcification is associated with incremental hazard for adverse clinical events, including death, during 5-10 years following PCI despite the use of new generation drug- eluting stents.
View Article and Find Full Text PDFCureus
November 2024
Cardiology, Lebanese American University School of Medicine, Beirut, LBN.
Drug-coated balloons (DCBs) represent a promising alternative to drug-eluting stents (DESs) by adopting a "leave-nothing-behind" approach, avoiding the long-term implantation of metallic materials associated with vessel damage, stent thrombosis, and restenosis. Although DCBs have historically been indicated for patients with in-stent restenosis or de novo small-vessel disease, recent studies indicate the potential for broader applications in acute coronary syndromes (ACSs). Trials comparing DCB and DES treatments show that DCBs yield comparable long-term outcomes, with some studies suggesting reduced rates of secondary endpoints such as cardiac death and non-fatal myocardial infarction among ACS patients treated with DCBs.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
December 2024
Department of Cardiology, Kettering General Hospital, Interventional Cardiologist, Kettering, Northamptonshire, UK.
G Ital Cardiol (Rome)
November 2024
S.C. Cardiologia, Ospedale S.G. Bosco, ASL Città di Torino, Torino.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!